Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta

NCT05972551 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

106

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteogenesis Imperfecta

Interventions

DRUG: Romosozumab
DRUG: Bisphosphonate

Sponsor

Amgen